Avexitide (Exendin 9-39) is an antagonist of glucagon-like peptide-1 (GLP-1) receptor, and also acts as an inhibitor of glucosedependent insulinotropic polypeptide (GIP)-receptor binding. Avexitide (Exendin 9-39) is a competitive inhibitor of exendin-3 and exendin-4. It also prevents the production of cAMP by GIP. GLP-1, along with GIP, acts as a physiological incretin. Avexitide (Exendin 9-39) has been used to study its effect on basal microvascular permeability.
Amino Acid Sequence
Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Molecular Weight | 3369.76 |
Formula | C149H234N40O47S |
CAS Number | 133514-43-9 |
Solubility (25°C) | Water 30 mg/mL |
Storage | -20°C, dry, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related GLP Receptor Products |
---|
Amycretin
Amycretin is a novel, potentially first-in-class, long-acting co-agonist of GLP-1 and the amyloid receptor (AMYR) for obesity-related studies. |
NM-003
NM-003 is a GLP-2R agonist that can be used in studies related to inflammatory bowel disease. |
NB-1002
NB-1002 is a GLP-2R agonist that can be used in studies related to short bowel syndrome. |
MOD-15014
MOD-15014 is a GLP-2R modulator that can be used in studies related to short bowel syndrome. |
HM-15912
HM-15912 is a GLP-2R agonist that can be used in studies related to short bowel syndrome. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.